Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA delays Prevnar 13 action to year end

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA moves the user fee action date for Wyeth's pneumococcal vaccine Prevnar 13 from Sept. 30 to Dec. 30 so it can consider additional information submitted at the agency's behest in July, the drug maker announces Aug. 11. The data constitute a major amendment to the BLA submitted in March (1"The Pink Sheet" DAILY, April 1, 2009). The amendment contains additional analytical method validation and specification information related to physical/chemical properties of the vaccine. The conjugate vaccine is under review for active immunization of infants and young children for prevention of invasive disease and otitis media caused by 13 Streptococcus pneumoniae serotypes, six more than the currently approved Prevnar, which has been available in the U.S. for over nine years

You may also be interested in...

Wyeth Files Prevnar 13 Vaccine With FDA; GSK Is Step Ahead With Synflorix In Europe

Wyeth is seeking a priority review for its 13-valent pneumococcal vaccine in the U.S., while GSK’s 10-valent version is approved in Europe.

‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

Warning Letter Roundup & Recap – 22 September 2020

No device-related warning letters were released by the US FDA the week of 22 September.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts